Novavax (NASDAQ: NVAX) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $9.2 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.